RESOMER RG 753 H Bioresorbable PLGA Drug Delivery Grade is a poly(D,L-lactide-co-glycolide) copolymer synthesized from a 75:25 molar ratio of D,L-lactide and glycolide and carrying a carboxylic acid chain terminus. The product is supplied as an amorphous white to off-white powder under the RESOMER trade name. The release specification for inherent viscosity is 0.32–0.44 dL/g, determined at 0.1% w/v in chloroform at 25 °C according to DIN EN ISO 1628-1. The 75:25 lactide:glycolide composition is less hydrophilic than 50:50 PLGA and degrades by bulk hydrolysis into lactic acid and glycolic acid, which enter established metabolic pathways.

Because the lactide portion is racemic D,L-lactide, the polymer does not develop spherulitic crystallinity. Differential scanning calorimetry can be used to confirm the absence of a crystalline melting endotherm; the glass transition is below 50 °C and is not necessarily the principal release parameter. For formulation development, molecular weight comparisons are made via gel permeation chromatography with refractive index detection and poly(methyl methacrylate) standards; absolute molar mass requires multi-angle laser light scattering. The carboxylic acid end group and amorphous character are central to the functional behavior of this grade.

Specification Profile Under Current Certificate of Analysis Documentation

The following parameters are representative of manufacturer release data for RESOMER RG 753 H. Because no harmonized pharmacopoeial monograph for PLGA exists, the lot-specific certificate of analysis remains the authoritative source.

Residual monomer, residual solvent, water content, and catalyst-derived tin are generally reported on the lot-specific certificate of analysis. The residual solvent statement follows ICH Q3C and USP 467; water content is determined by Karl Fischer titration using USP 921 Method Ic. Drug Delivery Grade documentation supports pharmaceutical excipient qualification, but endotoxin and bioburden are not guaranteed by the grade name alone and must be specified separately for parenteral use.

Primary packaging is typically sealed under dry inert gas to limit hydrolytic degradation during storage. Cold material should be equilibrated inside the sealed container before opening to prevent condensation on the powder surface. Unused material should not be returned to the original container because inert-gas packaging integrity is lost after opening.

How Does Acid Termination Modify Hydrolytic Degradation Compared with Ester-Capped Chains?

The free carboxylic acid end group in RG 753 H increases the concentration of ionized carboxyl species during water uptake and promotes autocatalytic hydrolysis of ester linkages. This mechanism produces a shorter initial hydrolysis lag than would be observed for an ester-capped 75:25 PLGA of similar chain length. The 75:25 lactide-rich composition concurrently lowers water uptake compared with 50:50 PLGA because the methyl side chains on lactide residues reduce hydrophilicity. Acid-terminated 75:25 PLGA therefore occupies a middle degradation window: faster initiation than ester-capped 75:25 PLGA and slower bulk mass loss than acid-terminated 50:50 PLGA of comparable inherent viscosity. Mass loss and release in phosphate-buffered saline at 37 °C are geometry-dependent, and no single release duration should be assigned to the raw polymer.

The polymer is soluble in dichloromethane, chloroform, acetone, ethyl acetate, and tetrahydrofuran. Ethyl acetate can be used to avoid chlorinated solvent residues, but the solution viscosity of RG 753 H in ethyl acetate can be higher than in dichloromethane at equivalent concentration. The optimum concentration for a given emulsion process should be determined by rotational rheometry at 25 °C and confirmed by gravimetric solids analysis.

In solvent-evaporation microencapsulation, solutions of RESOMER RG 753 H in dichloromethane are typically prepared at 5–20% w/w. The organic phase is dispersed into an aqueous continuous phase containing 1% w/v poly(vinyl alcohol) and 0.5% w/v sodium chloride using a rotor-stator disperser with a 10–20 mm generator at 10,000–25,000 min^-1. Extraction and hardening proceed at 25–30 °C for 4–6 h. Residual dichloromethane in the dried microspheres should be controlled below the 600 µg/g concentration limit defined in USP 467. Within the 0.32–0.44 dL/g viscosity band, lot-to-lot variation changes primary emulsion breakage and final particle size; the dispersing speed must be re-established after each polymer lot change. The carboxylic acid terminus can also interact with amine-containing peptide active pharmaceutical ingredients through acylation or electrostatic binding, so peptide integrity should be monitored by reversed-phase HPLC during preformulation stability.

For hydrophilic peptides, a water-in-oil-in-water double emulsion is preferred: an inner aqueous phase is dispersed into the polymer solution, followed by dispersion into the outer aqueous phase. The carboxylic acid terminus can modify pH at the inner water-oil interface; phosphate or citrate buffers are used to stabilize the peptide during solvent removal. After extraction, the microspheres are washed with cold water for injection, collected on a 20 µm sieve, and dried under vacuum at 25 °C or freeze-dried when the active pharmaceutical ingredient is thermally sensitive.

When 75:25 PLGA Replaces 50:50 in Emulsion-Solvent Extraction

Substitution of a 50:50 acid-terminated grade with RESOMER RG 753 H modifies solvent-water partitioning, water uptake, and hydrolytic chain scission rate. The following comparison assumes equivalent inherent viscosity and particle geometry.

Changing to RESOMER RG 753 H without adjustment of the hardening time can produce a denser surface skin because the more hydrophobic polymer precipitates at a different solvent removal rate. The release lag phase may extend, but published data for this specific configuration is limited; the manufacturer does not assign a fixed release duration. Hardening time, wash time, and residual solvent removal must be revalidated when the polymer is changed from 50:50 to 75:25.

Spray drying from ethyl acetate or acetone solutions has been applied to PLGA. Typical inlet temperatures are 55–65 °C and outlet temperatures are 35–40 °C; the collection chamber should be maintained below 30% relative humidity to prevent particle fusion. The absence of a defined melting point permits these solution-based drying processes, but residual solvent and particle agglomeration must be monitored after drying.

For melt extrusion and implant molding, RESOMER RG 753 H is pre-dried under vacuum at 25 °C until residual moisture is below 0.5% w/w by USP 921 Method Ic. A co-rotating twin-screw extruder with an L/D ratio of 30:1 and gravimetric feeding is used, and the barrel temperature is kept below the onset temperature of 1% mass loss measured by thermogravimetric analysis for the specific lot. Processing under simultaneous high temperature and high shear accelerates hydrolytic chain scission; melt residence time should be minimized and should not exceed 5 min. At ambient relative humidity above 60%, cold polymer must be equilibrated in the sealed container before opening to prevent condensation. Dry heat sterilization and high-temperature injection molding without moisture control are outside the normal operating boundary.

Regulatory Documentation, Elemental Impurity Control, and Sterilization Boundaries

Drug Delivery Grade documentation includes a certificate of analysis, material safety data sheet, TSE/BSE statement, and residual solvent statement. Residual solvents are evaluated under ICH Q3C and USP 467. Elemental impurities, including catalyst-derived tin, are assessed under ICH Q3D; the grade itself does not automatically provide compendial compliance for every pharmaceutical formulation because no harmonized PLGA monograph exists. Specification limits, retest dates, and packaging configuration are agreed between the supplier and the pharmaceutical user. Manufacturing is supported by quality systems aligned with ISO 13485:2016 and pharmaceutical excipient good manufacturing practice, and the documentation supports qualification under 21 CFR 210/211 for drug product manufacturing.

Terminal sterilization by gamma irradiation can lower molecular weight through chain scission. Dose setting and validation follow ISO 11137-2:2013; the required dose is product-specific and should be verified on the final packaged device rather than on raw polymer. E-beam irradiation can also degrade the polymer. Sterile filtration of this grade is possible only at low polymer concentration when the solution viscosity permits passage through a 0.22 µm membrane; no universal filter capacity should be assumed.

Combination of RESOMER RG 753 H with amine-functionalized active pharmaceutical ingredients or strong bases should be avoided unless compatibility is demonstrated. Free amines promote nucleophilic attack on ester linkages, and storage of mixed solutions can lead to rapid molecular weight loss and premature release. The polymer is also incompatible with strong oxidizing acids. Within the 75:25 acid-terminated family, a lower-viscosity grade such as RG 752 H may be more suitable for thin-walled microspheres and low-viscosity processing, whereas RG 753 H is selected when monolithic implants require higher chain length and greater mechanical integrity during handling. The suffix H indicates acid termination; users requiring an ester-capped chain should confirm the end-group specification before substitution.